Tectonic Therapeutic, INC Form 4 insider transactions

Peter Mcnamara, Chief Scientific Officer of Tectonic Therapeutic, Inc., sold 43 shares of common stock on August 12, 2026 for $35.00 per share.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, executed a stock transaction under a pre-arranged Rule 10b5-1 trading plan.

Tectonic Therapeutic, Inc. director Timothy A. Springer acquired stock options for 10,200 shares of common stock.

Praveen P. Tipirneni, a Director at Tectonic Therapeutic, Inc., acquired 10,200 stock options with an exercise price of $28.56.

Phillip B. Donenberg, a Director at Tectonic Therapeutic, Inc., acquired 10,200 stock options.

Stefan Vitorovic, a Director at Tectonic Therapeutic, Inc., has acquired stock options for 10,200 shares of common stock.

Tectonic Therapeutic, Inc. reports the grant of stock options to Director Jessica Caroline Chutter.

Chief Medical Officer Marcella K. Ruddy sold 1,065 shares of Tectonic Therapeutic, Inc. common stock under a pre-arranged 10b5-1 plan.

Marcella K. Ruddy, Chief Medical Officer of Tectonic Therapeutic, Inc., sold 1,000 shares of common stock for $31,050 on April 1, 2026, under a pre-arranged trading plan.

Director Francois Nader of Tectonic Therapeutic, Inc. acquired stock options for 20,400 shares.

Tectonic Therapeutic CEO Alise Reicin acquired 76,500 restricted stock units and 69,250 employee stock options, signaling continued commitment to the company.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, was granted 19,500 restricted stock units and options to purchase 17,750 shares of common stock.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, reported sales of common stock and the acquisition of restricted stock units and employee stock options.

Tectonic Therapeutic's Chief Financial Officer, Daniel Lochner, received significant equity grants including restricted stock units and stock options, increasing his beneficial ownership.

Tectonic Therapeutic's Chief Medical Officer, Marcella K. Ruddy, received 26,500 restricted stock units and 24,250 employee stock options.

Tectonic Therapeutic CEO Alise Reicin amended a Form 4 to clarify that a recent 2,500 share purchase was made indirectly through a family trust, not directly.

Tectonic Therapeutic, Inc. CEO Alise Reicin purchased 2,500 shares of common stock at an average price of $21.10, signaling confidence in the company.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, acquired 4,500 shares of common stock through option exercise.

Tectonic Therapeutic's Chief Financial Officer, Daniel Lochner, purchased 6,000 shares of common stock, signaling increased insider confidence.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, disposed of 1,619 common shares to cover tax obligations related to restricted stock unit vesting.

Tectonic Therapeutic's Chief Medical Officer, Marcella K. Ruddy, disposed of 2,064 shares of common stock to cover tax obligations related to RSU vesting.

Tectonic Therapeutic CEO Alise Reicin disposed of 4,104 shares of common stock to cover tax withholding obligations related to RSU vesting.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, disposed of 1,748 common shares to cover tax liabilities from RSU vesting.

Alise Reicin, CEO of Tectonic Therapeutic, exercised employee stock options to acquire 10,966 shares of common stock at $2.38 per share under a pre-arranged 10b5-1 plan.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, exercised 7,000 employee stock options at $2.98 per share.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, received new equity awards including restricted stock units and stock options.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, acquired 4,550 restricted stock units and 8,260 employee stock options.

Tectonic Therapeutic's CFO, Daniel Lochner, acquired 5,430 restricted stock units and 9,860 employee stock options, increasing his beneficial ownership.

Tectonic Therapeutic's Chief Medical Officer, Marcella K. Ruddy, received grants of restricted stock units and employee stock options on September 25, 2025.

Tectonic Therapeutic CEO Alise Reicin received grants of 14,700 restricted stock units and options for 26,710 shares.